The 2024 outlook for not-for-profit hospital and health systems improved from negative to stable, in part, due to the planned [...] …
Category: Research/Reports
The average hospital in the 340B program charges commercial insurers more than non-340B hospitals, according to a new report, which [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Enrollment in the 340B program was linked to diminished spending on charity care, according to preliminary findings from an ongoing [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The community benefits provided by 340B hospitals surged by $16.5 billion, or 24%, in the latest year analyzed by a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The majority of 340B disproportionate share hospitals (DSH) provide charity care at lower rates than the national hospital average, found [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Timelines for manufacturers to provide new Medicare “maximum fair prices” (MFPs) and 340B ceiling prices on drugs are misaligned, risking [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A recent study found positive patient benefits from a 340B cash discount program. Low-income patients said saving money on injectable [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A leading senator and two major hospital trade groups recently published conflicting reports on the level of community benefit that [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Researchers rejected criticism of a recent study in an academic journal they co-authored from the leader of a 340B hospital [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug purchases under the 340B program totaled $53.7 billion in 2022, or 22.3% more than the $43.9 billion in 2021, [...] …